Immunovant Phase II Data on Batoclimab Show Promise for MG and CIDP as IMVT-1402 Prepares for More Trials
Kieran Lockhart, Jun, 15 2025
Immunovant’s Phase II trials saw batoclimab outperform in both myasthenia gravis and CIDP, with further promise in Graves’ disease. Now, the company is pushing its new asset, IMVT-1402, into more advanced trials, aiming to set a new standard for autoimmune disease treatment.
Categories:
Tags:
